-
Cyclosporin A in Mitophagy Workflows
2026-09-09
Cyclosporin A, also known as cyclosporine, gives researchers a practical cyclophilin-centered perturbation for separating mitochondrial protection from downstream inflammatory effects. This guide translates a chondrocyte gout study into reproducible cell-assay workflows while extending the reagent’s value to immune signaling, apoptosis modulation, and carefully bounded translational models.
-
In Vitro Drug Response: Viability, Growth, and Cell Death
2026-09-09
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating growth inhibition from cell killing and for interpreting their different magnitudes and time courses in vitro.
-
Light-Inducible RNA Switches for Regulated Gene Therapy
2026-09-08
The reference study presents a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic gene expression at the translational level. In mouse models, LIRP enabled ambient-light regulation of metabolic therapy and reversible interruption of retinal VEGF inhibition, illustrating how optogenetic gene switches may improve timing and safety in gene therapy.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-08
This study identifies an LMO2/LDB1 protein complex as a functional regulator of acute myeloid leukemia cell growth and survival. Its combination of perturbation experiments, protein-interaction analysis, transcriptomics, and chromatin profiling supports LDB1 as an oncogenic co-regulator and clarifies how LMO2 may contribute to AML maintenance.
-
N1-Methylpseudo-UTP for Translational mRNA
2026-09-07
N1-Methylpseudo-UTP enables controlled uridine modification during IVT to support RNA stability enhancement and translation-focused assays. Its value extends from mRNA vaccine development and RNA translation mechanism research to localized therapeutic studies such as the p21-LNP bladder cancer model.
-
Chemotherapy Enhances Neoantigen T Cell Therapy
2026-09-07
Sagie et al. identify the KRAS.G12V-specific TCR T104 and show that lymphodepleting chemotherapy can improve neoantigen visibility by increasing immunoproteasome activity and HLA-I surface expression. The findings provide a mechanistic rationale for combining conditioning chemotherapy with TCR-T cells, tumor-infiltrating lymphocytes, or T cell engagers, while also defining important translational limitations.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-09-05
The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors. By combining pharmacological inhibition, mass cytometry, mouse injury models, and transcriptomic network analysis, it shows how restoring β-catenin activity can limit pathological fat accumulation and improve FAP support of muscle regeneration.
-
nor-Binaltorphimine Dihydrochloride for KOR Studies
2026-09-04
Use nor-Binaltorphimine dihydrochloride to isolate κ-opioid receptor contributions in receptor assays and circuit-informed pain models. This guide connects practical antagonist workflows with the brain-to-spinal pathway linked to morphine-induced mechanical hypersensitivity and tolerance.
-
Capecitabine for Preclinical Oncology
2026-09-04
Capecitabine is a fluoropyrimidine prodrug whose enzymatic activation generates 5-fluorouracil for oncology research. Its activation biology, Fas-associated apoptosis evidence, and compatibility with patient-derived tumor–stroma models support structured studies of selective cytotoxicity and treatment resistance.
-
Bacillus Media Shape γ-Glutamyl Peptide Production
2026-09-03
The 2024 Food Bioscience study shows that both Bacillus strain identity and growth-medium composition influence γ-glutamyl peptide formation, with hemoglobin hydrolysate generally supporting higher peptide concentrations than brain heart infusion broth. Its main practical contribution is a comparative fermentation framework for linking substrate availability, bacterial growth, glutamyltransferase activity, and kokumi-related peptide production.
-
Palonosetron for Chemotherapy-Induced Nausea and Vomiting
2026-09-03
Fabi and Malaguti’s 2013 review positions palonosetron as a distinctive 5-HT3 receptor antagonist because of its high receptor-binding affinity and prolonged half-life, with particular relevance to delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy. The article also clarifies how emetogenic risk, symptom timing, neurobiology, combination therapy, and clinical guidelines should shape antiemetic decisions.
-
ω-Agatoxin IVA TFA: Precision in Cav2.1 Research
2026-09-02
ω-Agatoxin IVA TFA provides a selective experimental handle on Cav2.1-dependent calcium entry, enabling researchers to connect channel subtype activity with neurotransmitter release, seizure circuitry, and neuroprotective hypotheses. This thought-leadership perspective outlines how to use omega-agatoxin IVA strategically while separating mechanistic evidence from translational assumptions.
-
DIDS: A Practical Guide to Chloride-Transport Assays
2026-09-02
DIDS connects chloride-transport pharmacology with cell-death, tumor, vascular, and sensory-neuron workflows. This guide shows how to handle its challenging solubility, separate channel effects from state-selection artifacts, and translate dose-response data into reproducible experiments.
-
Imatinib (STI571) Workflow for Kinase Assays
2026-09-01
Imatinib (STI571) provides a practical perturbation tool for dissecting PDGF receptor, c-Kit, and Abl signaling across biochemical, cellular, and translational models. This workflow connects phospho-protein measurements with proliferation, migration, and remodeling phenotypes while highlighting controls that improve reproducibility.
-
gamma-Glu-Cys (γ-Glu-Cys) Lab Guide
2026-09-01
gamma-Glu-Cys (γ-Glu-Cys) provides a defined intermediate for glutathione metabolism research, glutathione synthetase enzyme assays, and selected phytochelin-related workflows. It is intended for controlled scientific research with freshly prepared solutions, not for diagnostic, clinical, medical, or therapeutic use.